Small Cap Hong Kong (HSI) Pharmaceuticals & Biotech Stocks by Market Cap

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
1889 Sanai Health Industry Group	HK$0.33	-2.9%	-73.6%	HK$50.5m	n/a	PE3.6x	n/a	n/a
1011 China NT Pharma Group	HK$0.23	-1.3%	-51.1%	HK$60.7m	n/a	PS1.8x	n/a	0%
1228 CANbridge Pharmaceuticals	HK$0.15	7.9%	-65.5%	HK$63.7m	n/a	PE-0.1x	n/a	n/a
8158 China Regenerative Medicine International	HK$0.27	0%	-34.6%	HK$80.6m	n/a	PS1.5x	n/a	n/a
8247 Biosino Bio-Technology and Science Incorporation	HK$0.62	0%	-7.5%	HK$89.7m	n/a	PB0.4x	n/a	0%
575 Regent Pacific Group	HK$0.42	-16.7%	-18.3%	HK$97.1m	n/a	PS244.8x	n/a	n/a
858 Extrawell Pharmaceutical Holdings	HK$0.047	-2.1%	11.9%	HK$112.3m	n/a	PE0.6x	n/a	n/a
1312 Kontafarma China Holdings	HK$0.028	-9.7%	-22.2%	HK$156.5m	n/a	PB0.1x	n/a	0%
8225 China Health Group	HK$0.17	-8.4%	23.4%	HK$173.2m	n/a	PS6.5x	n/a	n/a
1498 PuraPharm	HK$0.55	3.8%	-32.9%	HK$217.3m	n/a	PB1.7x	n/a	0%
1652 Fusen Pharmaceutical	HK$0.32	-18.2%	-75.4%	HK$232.9m	n/a	PB0.4x	n/a	0%
1643 Modern Chinese Medicine Group	HK$0.39	0%	14.7%	HK$234.0m	n/a	PE15.2x	n/a	0%
8329 Shenzhen Neptunus Interlong Bio-technique	HK$0.16	-3.1%	-3.1%	HK$261.8m	n/a	PE7.6x	n/a	n/a
690 Uni-Bio Science Group	HK$0.053	-5.4%	-40.4%	HK$316.5m	n/a	PE3.2x	n/a	n/a
6628 Transcenta Holding	HK$0.80	17.6%	-69.3%	HK$323.4m	HK$9.11	PS13.5x	E11.6%	n/a
2257 Sirnaomics	HK$3.48	37.5%	-82.6%	HK$363.1m	HK$72.10	PS43.3x	S50.7%	n/a
455 Tianda Pharmaceuticals	HK$0.18	0%	-11.1%	HK$397.8m	n/a	PS1x	n/a	1.4%
6118 Austar Lifesciences	HK$0.84	44.8%	-47.8%	HK$430.6m	n/a	PB0.5x	n/a	0%
897 Wai Yuen Tong Medicine Holdings	HK$0.39	4.1%	-7.2%	HK$433.2m	n/a	PE209.1x	n/a	7.8%
2197 Clover Biopharmaceuticals	HK$0.37	51.0%	-16.9%	HK$479.9m	n/a	PS15.5x	n/a	n/a
9939 Kintor Pharmaceutical	HK$1.14	21.3%	-23.5%	HK$493.6m	n/a	PB1.2x	n/a	n/a
2898 Sunho Biologics	HK$3.89	-2.8%	n/a	HK$586.1m	n/a	PS47.3x	n/a	n/a
2511 HighTide Therapeutics	HK$1.32	13.8%	-88.3%	HK$679.5m	n/a	PB1.2x	n/a	n/a
950 Lee's Pharmaceutical Holdings	HK$1.30	8.3%	0%	HK$765.5m	n/a	PE12.1x	n/a	2.3%